Which molecular biomarkers do you favor to risk stratify patients (without CV risk factors) before and after undergoing treatment with cardiotoxic cancer treatments?
Answer from: at Academic Institution
In general, troponin, NTproBNP or BNP, and lipid panel are the main biomarkers I use for CV risk stratification prior to cancer therapy. Baseline troponin and NTproBNP are primarily useful for cancer therapies that may cause cardiomyopathy or myocarditis (i.e. anthracyclines, anti-HER2 therapies, VE...
Sign in or Register to read more